Donate

Media center

At PATH, our global health experts are developing partnerships, new devices, and solutions to the world's most pressing health needs. Contact us to speak with one of PATH's experts today.

Contact Us

Senior Director of Marketing & Communications:
Lauren Grella

Email: media@path.org

PATH is advancing health equity around the world

April 2, 2025
Uganda launches Africa’s largest malaria vaccine rollout to date
March 25, 2025
Fewer shots, more protection: The promise of combination vaccines
March 20, 2025
How local heroes are reshaping disability care in Mozambique

Stay informed with PATH Insights

Featured Press Coverage

April 18, 2024
Millions of Girls in Africa Will Miss HPV Shots After Merck Production Problem
The New York Times
February 8, 2024
Good intentions, bad outcomes: The dangers of donated medical devices
Devex
February 12, 2024
Could new vaccines end malaria in Africa?
Al Jazeera

Recent Press Coverage

  1. The looming antibiotic emergency and why the time for global action is now
    PATH’s Nikolaj Gilbert and Dame Sally Davies write in The Telegraph about drug-resistant infections that are outpacing our ability to treat them—and how the global community must come together to address this growing global threat.
    Published: March 2025
  2. PATH part of $12.7M GHIT Fund initiative for malaria, NTDs research.
    PATH is among the global partners receiving funding from the GHIT Fund’s $12.7 million investment to advance new diagnostics and drug development for malaria and neglected tropical diseases (NTDs).
    Published: January 2025
  3. Opinion: GenAI for global health — the bear and the bull case
    Dr. Bilal Mateen, PATH’s Chief AI Officer, highlights GenAI’s potential in diagnostics, disease surveillance, and health communication while addressing challenges like data privacy and equity.
    Published: December 2024
  4. Life-saving advances in vaccines pave the way for healthier futures
    Dr. Cathy Ndiaye, Director of HPV Vaccine Programs at PATH, shares her personal connection to the fight against cervical cancer and her efforts to address disparities in prevention and care.
    Published: November 2024
Next

We develop evidence-based expertise and resources

Our global team leverages data and evidence to develop resources and innovations that bring good health to more people.

Explore our evidence

Join the latest discussions on health equity.

We partner with the public and private sector, government, and academia from around the world to share insightful conversations on the latest topics affecting health equity.

Explore PATH events

PATH Newsroom

Related articles

Read our latest

948 Item s
948 Item s
    Date
    From
    To
  1. PATH welcomes commitment by Gavi board to finance wider rollout of the world’s first malaria vaccine, RTS,S
    Published: December 2021
    Press Release
  2. PATH and the Helmsley Charitable Trust partner to improve access to safe administration of insulin and self-care for people living with diabetes
    A century after the discovery of insulin, millions of people living with diabetes cannot obtain or afford the necessary supplies to self-manage their diabetes on a day-to-day basis. PATH partners with the Helmsley Charitable Trust to improve access to diabetes self-care in Mali, Mozambique, and Tanzania.
    Published: November 2021
    Press Release
  3. A supply gap of more than 1 billion autodisable syringes could impact COVID-19 immunization efforts in 100 countries
    Global convening of syringe manufacturers and multilateral organizations held to help bolster supply.
    Published: November 2021
    Press Release
  4. PATH congratulates India on nationwide pneumococcal vaccine introduction
    Routine childhood immunization with pneumococcal vaccines is a critical step in India's fight against pneumonia and other pneumococcal diseases.
    Published: November 2021
    Statement
  5. New panel of antibodies available to support the development of affordable pneumococcal vaccines
    New high-quality and affordable serotype-specific monoclonal antibodies (mAbs) now globally available to support vaccine manufacturers in the development of pneumococcal vaccines
    Published: November 2021
    Press Release
Previous
Next